510(k) · Cleared
ClearedMra-CMS
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly
Medis Medical Imaging Systems BV · LLZ System, Image Processing, Radiological
Cleared on Jun 8, 2004 as substantially equivalent to K002519 (Vital Images, Inc., 2000) after a 77-day review. Its family tree reaches back 1 generation to 2000. 2 later devices descend from it.
- Decided
- Jun 8, 2004
- Review
- 77 days
- Class
- Class II
- Product code
- LLZ
- Recalls
- None
- Predicates
- 1
Its longest line of descent runs back 1 generation to K002519 (2000). 2 later devices descend from it, 2 citing it directly.
- Root · 1 generation backK002519 Vitrea 2, Version 2.1Vital Images, Inc. · 2000 · Recalled
- This deviceK040746 Mra-CMSMedis Medical Imaging Systems BV · 2004
- Descendant · cites it directly · 0 of its ownK122164 MR Vessellq XpressGE Medical Systems SCS · 2012
- Descendant · cites it directly · 0 of its ownK062386 Qangio CTMedis Medical Imaging Systems BV · 2006
Most influential descendants
Showing 2 of 2 · See allView FIG. 1 as a table
Line of descent and top descendants
| Generation | Number | Device | Applicant | Decided | Recalls |
|---|---|---|---|---|---|
| −1 | K002519 | Vitrea 2, Version 2.1 | Vital Images, Inc. | 2000 | 1 |
| 0 (this device) | K040746 | Mra-CMS | Medis Medical Imaging Systems BV | 2004 | — |
| +1 | K122164 | MR Vessellq Xpress | GE Medical Systems SCS | 2012 | — |
| +1 | K062386 | Qangio CT | Medis Medical Imaging Systems BV | 2006 | — |
Descendants by year cleared
| Year cleared | Devices | With a Class I recall |
|---|---|---|
| 2006 | 1 | 0 |
| 2012 | 1 | 0 |
Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.
Planning a device in LLZ? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.
Top candidate predicates for a new LLZ device
- #1 K230955 syngo Application Softwarescore 21.5 · 11 generations · no Class I recall
- #2 Held for the reportin the report
- #3 Held for the reportin the report
What was it cleared against? (1)
Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.
| Type | Number | Device | Decided |
|---|---|---|---|
| * | K002519 | Vitrea 2, Version 2.1Summary page 1…e :MRA-CMS Common Name :MRA Classification Name 90 LLZ (21 CFR 892.2050) 3. Predicate Device(s) :Vital Images: 510(k) K002519 4. Description of the device: MRA-CMS can be utilized to determine lumen lengths; minimum and maximum cross sectional diameters… | 2000 |
What descends from it? (2)
2 later devices cite it directly; ranked here by how many devices descend from each in turn.
Has anything in its family been recalled? (0 Class I)
No FDA recall names this device.
No ancestor or descendant has a Class I recall.
What does this lineage say?
How does its category compare?
All LLZ devicesLLZ System, Image Processing, Radiological: FDA decisions, review times, recalls and adverse event reports over 20 years.
FDA decisions per year · LLZ
58in 2025
2026 to Oct 25, outlined.
Median 510(k) review, days · LLZ
173in 2025
Receipt to decision; years with fewer than 3 clearances left blank.
Recalls per year · LLZ
11in 2025
Class I (0 since 2007) Class II/III not classified
Adverse event reports per year · LLZ
116in 2025
MAUDE reports naming product code LLZ, not matched to any one device; reports are not rates.
View these four charts as a table
| Year | Decisions | Median 510(k) review, days | Recalls (Class I) | MAUDE reports |
|---|---|---|---|---|
| 2007 | 76 | 36 | 20 | 152 |
| 2008 | 94 | 52 | 32 | 154 |
| 2009 | 70 | 62 | 21 | 145 |
| 2010 | 51 | 98 | 17 | 145 |
| 2011 | 106 | 79 | 30 | 454 |
| 2012 | 82 | 87 | 12 | 266 |
| 2013 | 95 | 84 | 64 | 1,130 |
| 2014 | 78 | 89 | 6 | 15,631 |
| 2015 | 64 | 90 | 16 | 211 |
| 2016 | 82 | 90 | 12 | 290 |
| 2017 | 78 | 107 | 5 | 104 |
| 2018 | 104 | 105 | 7 | 72 |
| 2019 | 74 | 107 | 2 | 88 |
| 2020 | 81 | 115 | 6 | 82 |
| 2021 | 83 | 116 | 3 | 70 |
| 2022 | 65 | 137 | 4 | 28 |
| 2023 | 87 | 157 | 8 | 26 |
| 2024 | 62 | 131 | 6 | 42 |
| 2025 | 58 | 173 | 11 | 116 |
| 2026 | 45 | 110 | 14 | — |
What is it indicated for?
MRA has been developed for the objective and reproducible analysis of MRA data
The intended purposes are:
1. Supporting clinical diagnoses about the status of the global and regional function and anatomy of the human heart;
2. Supporting the subsequent clinical decision making processes;
3. Supporting the use in clinical research trials, directed at studying changes in function and anatomy of the heart chambers as a result of treatment.
Indications for use as stated in the FDA summary.
https://510kreport.com/device/K040746 · printed Nov 5, 2026
Cite this page
510(k) Report. “K040746: Mra-CMS.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 5, 2026. https://510kreport.com/device/K040746
Report an extraction error
Are you the manufacturer?
Record history
- FDA decision record loaded May 2, 2026
- Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
- Lineage and recalls computed Nov 3, 2026
- Page last updated Nov 3, 2026